MicroRNAs in abdominal aortic aneurysm

Current Vascular Pharmacology

Volumn 13, Issue 3, 2015, Pages 280-290

  Adam, Matti ^a   Raaz, Uwe ^a   Spin, Joshua M ^a   Tsao, Philip S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abdominal aortic aneurysms; Cardiovascular medications; Endovascular repair; MicroRNA; Therapeutic approaches; Vascular pathobiology

Indexed keywords

ANTAGOMIR; CATHEPSIN S; D DIMER; FIBRINOGEN; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MICRORNA; MICRORNA 132; MICRORNA 133; MICRORNA 142 3P; MICRORNA 146A; MICRORNA 148 3P; MICRORNA 152; MICRORNA 17 92; MICRORNA 181; MICRORNA 188; MICRORNA 204; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 26A; MICRORNA 29B; MICRORNA 301A; MICRORNA 34B; MICRORNA 497; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL AORTA ANEURYSM; APOPTOSIS; ARTICLE; BIOLOGICAL MODEL; DOWN REGULATION; ENDOTHELIUM CELL; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; INFLAMMATORY CELL; NONHUMAN; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; PATHOLOGY;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; HUMANS; MICRORNAS;

EID: 84937125891     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990015     Document Type: Article

References (96)

1. [1] Johnston KW, Rutherford RB, Tilson MD, Shah DM, Hollier L, Stanley JC. Suggested standards for reporting on arterial aneurysms. J Vasc Surg 1991; 13(3): 452-8.
2. [2] Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006; 47(6): 1239-312.
3. [3] Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 2011; 8(2): 92-102.
4. [4] Anjum A, von Allmen R, Greenhalgh R, Powell JT. Explaining the decrease in mortality from abdominal aortic aneurysm rupture. Br J Surg 2012; 99(5): 637-45.
5. [5] Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 2012; 125(1): e2-e220.
6. [6] Schermerhorn ML, Bensley RP, Giles KA, et al. Changes in abdominal aortic aneurysm rupture and short-term mortality, 1995-2008: a retrospective observational study. Ann Surg 2012; 256(4): 651-8.
7. [7] Mohan PP, Rozenfeld M, Kane RA, Calandra JD, Hamblin MH. Nationwide trends in abdominal aortic aneurysm repair and use of endovascular repair in the emergency setting. J Vasc Interv Radiol 2012; 23(3): 338-44.
8. [8] Fleming C, Whitlock EP, Beil TL, Lederle FA. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. preventive services task force. Ann Intern Med 2005; 142(3): 203-11.
9. [9] Cornuz J, Sidoti Pinto C, Tevaearai H, Egger M. Risk factors for asymptomatic abdominal aortic aneurysm: Systematic review and meta-analysis of population-based screening studies. Eur J Pub Health 2004; 14(4): 343-9.
10. [10] Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997; 126(6): 441-9.
11. [11] Wong DR, Willett WC, Rimm EB. Smoking, hypertension, alcohol consumption, and risk of abdominal aortic aneurysm in men. Am J Epidemiol 2007; 165(7): 838-45.
12. [12] MacSweeney STR, Ellis M, Worrell PC, Greenhalgh RM, Powell JT. Smoking and growth rate of small abdominal aortic aneurysms. Lancet 1994; 344(8923): 651-2.
13. [13] Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Rterioscler Thromb Vasc Biol 2006; 26(12): 2605-13.
14. [14] Golledge J, van Bockxmeer F, Jamrozik K, McCann M, Norman PE. Association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol 2010; 105(10): 1480-4.
15. [15] Sweeting MJ, Thompson SG, Brown LC, Powell JT, collaborators R. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg 2012; 99(5): 655-65.
16. [16] Flondell-Site D, Lindblad B, Gottsater A. High levels of endothelin (ET)-1 and aneurysm diameter independently predict growth of stable abdominal aortic aneurysms. Angiology 2010; 61(4): 324-8.
17. [17] Western CE, Carlisle J, McCarthy RJ, Currie IC. Palliation of abdominal aortic aneurysms in the endovascular era. Eur J Vasc Endovasc Surg 2013; 45(1): 37-43.
18. [18] Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006; 26(5): 987-94.
19. [19] Prisant LM, Mondy JS. Abdominal aortic aneurysm. J Clin Hypertens (Greenwich) 2004; 6(2): 85-9.
20. [20] Ghorpade A, Baxter BT. Biochemistry and molecular regulation of matrix macromolecules in abdominal aortic aneurysms. Ann N Y Acad Sci 1996; 800(1): 138-50.
21. [21] McDonald DA. Regional pulse-wave velocity in the arterial tree. J Appl Physiol 1968; 24(1): 73-8.
22. [22] Thomas M, Gavrila D, McCormick ML, et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 2006; 114(5): 404-13.
23. [23] Sharma AK, Lu G, Jester A, et al. Experimental abdominal aortic aneurysm formation is mediated by il-17 and attenuated by mesenchymal stem cell treatment. Circulation 2012; 126(11 Suppl 1): S38-S45.
24. [24] Harrison SC, Smith AJP, Jones GT, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J 2013; 34(48): 3707-16.
25. [25] Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005; 11(12): 1330-8.
26. [26] Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23(3): 483-8.
27. [27] Satta J, Haukipuro K, Kairaluoma MI, Juvonen T. Aminoterminal propeptide of type III procollagen in the follow-up of patients with abdominal aortic aneurysms. J Vasc Surg 1997; 25(5): 909-15.
28. [28] Kunieda T, Minamino T, Nishi J, et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation 2006; 114(9): 953-60.
29. [29] Ailawadi G, Moehle CW, Pei H, et al. Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J Thorac Cardiovasc Surg 2009; 138(6): 1392-9.
30. [30] Moxon JV, Parr A, Emeto TI, Walker P, Norman PE, Golledge J. Diagnosis and monitoring of abdominal aortic aneurysm: current status and future prospects. Curr Probl Cardiol 2010; 35(10): 512-48.
31. [31] Buijs RV, Willems TP, Tio RA, et al. Current state of experimental imaging modalities for risk assessment of abdominal aortic aneurysm. J Vasc Surg 2013; 57(3): 851-9.
32. [32] Freestone T, Turner RJ, Higman DJ, Lever MJ, Powell JT. Influence of hypercholesterolemia and adventitial inflammation on the development of aortic aneurysm in rabbits. Arterioscler Thromb Vasc Biol 1997; 17(1): 10-7.
33. [33] Wang Y, Krishna S, Golledge J. The calcium chloride-induced rodent model of abdominal aortic aneurysm. Atherosclerosis. 2013; 226(1): 29-39.
34. [34] Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, et al. Animal models of cardiovascular diseases. J Biomed Biotechnol 2011; 2011: 497-841.
35. [35] Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental aneurysms in rats. Circulation 1990; 82(3): 973-81.
36. [36] Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000; 105(11): 1641-9.
37. [37] Daugherty A, Cassis LA, Lu H. Complex pathologies of angiotensin II-induced abdominal aortic aneurysms. J Zhejiang Univ Sci B 2011; 12(8): 624-8.
38. [38] Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75(5): 843-54.
39. [39] Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000 02/24/print; 403(6772): 901-6.
40. [40] Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75(5): 855-62.
41. [41] Ambros V. The functions of animal microRNAs. Nature 2004; 431(7006): 350-5.
42. [42] Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Research. 2008 January 1, 2008; 36(suppl 1): D154-D8.
43. [43] Lund E, Dahlberg JE. Substrate selectivity of exportin 5 and dicer in the biogenesis of microRNAs. Cold Spring Harb Symp Quant Biol 2006; 71: 59-66.
44. [44] Griffiths-Jones S, Hui JH, Marco A, Ronshaugen M. MicroRNA evolution by arm switching. EMBO Rep 2011; 12(2): 172-7.
45. [45] Yang J-S, Phillips MD, Betel D, et al. Widespread regulatory activity of vertebrate microRNA* species. RNA 2011; 17(2): 312-26.
46. [46] Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110(3): 483-95.
47. [47] Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11(4): 252-63.
48. [48] Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136(4): 642-55.
49. [49] Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9(2): 102-14.
50. [50] Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136(2): 215-33.
51. [51] Voinnet O. Origin, biogenesis, and activity of plant microRNAs. Cell 2009; 136(4): 669-87.
52. [52] Brodersen P, Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol 2009; 10(2): 141-8.
53. [53] Hon LS, Zhang Z. The roles of binding site arrangement and combinatorial targeting in microRNA repression of gene expression. Genome Biol 2007; 8(8): R166.
54. [54] Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA; 105(30): 10513-8.
55. [55] Zampetaki A, Mayr M. Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb Haemost 2012; 108(4): 592-8.
56. [56] Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3(1): 1.
57. [57] van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012; 11(11): 860-72.
58. [58] Albinsson S, Skoura A, Yu J, et al. Smooth muscle miRNAs are critical for post-natal regulation of blood pressure and vascular function. PLoS One 2011; 6(4): e18869.
59. [59] Albinsson S, Suarez Y, Skoura A, Offermanns S, Miano JM, Sessa WC. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler Thromb Vasc Biol 2010; 30(6): 1118-26.
60. [60] Nazari-Jahantigh M, Wei Y, Schober A. The role of microRNAs in arterial remodelling. Thromb Haemost 2012; 107(4): 611-8.
61. [61] Liu G, Huang Y, Lu X, et al. Identification and characteristics of microRNAs with altered expression patterns in a rat model of abdominal aortic aneurysms. Tohoku J Exp Med 2010; 222(3): 187-93.
62. [62] Yoshimura K, Aoki H, Ikeda Y, Furutani A, Hamano K, Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase in mice. Ann N Y Acad Sci 2006; 1085: 74-81.
63. [63] Maegdefessel L, Azuma J, Toh R, et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med 2012; 4(122): 122ra22.
64. [64] Song J, Hu B, Qu H, Bi C, Huang X, Zhang M. Mechanical stretch modulates microRNA 21 expression, participating in proliferation and apoptosis in cultured human aortic smooth muscle cells. PLoS One 2012; 7(10): e47657.
65. [65] Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, Raj JU. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 2010; 299(6): L861-71.
66. [66] Wang F, Zhao XQ, Liu JN, et al. Antagonist of microRNA-21 improves balloon injury-induced rat iliac artery remodeling by regulating proliferation and apoptosis of adventitial fibroblasts and myofibroblasts. J Cell Biochem 2012; 113(9): 2989-3001.
67. [67] Wang M, Li W, Chang GQ, et al. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol 2011; 31(9): 2044-53.
68. [68] Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454(7200): 56-61.
69. [69] Maegdefessel L, Azuma J, Toh R, et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 2012; 122(2): 497-506.
70. [70] Boon RA, Seeger T, Heydt S, et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res 2011; 109(10): 1115-9.
71. [71] Chen KC, Wang YS, Hu CY, et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB 2011; 25(5): 1718-28.
72. [72] Fang JH, Zhou HC, Zeng C, et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 2011; 54(5): 1729-40.
73. [73] Leeper NJ, Raiesdana A, Kojima Y, et al. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol 2011; 226(4): 1035-43.
74. [74] Pahl MC, Derr K, Gabel G, et al. MicroRNA expression signature in human abdominal aortic aneurysms. BMC Med Genomics 2012; 5: 25.
75. [75] Tomasini R, Samir AA, Carrier A, et al. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem 2003; 278(39): 37722-9.
76. [76] Spin JM, Hsu M, Azuma J, et al. Transcriptional profiling and network analysis of the murine angiotensin II-induced abdominal aortic aneurysm. Physiol Genomics 2011; 43(17): 993-1003.
77. [77] Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia 2012; 17(1): 65-77.
78. [78] Nicoli S, Knyphausen CP, Zhu LJ, Lakshmanan A, Lawson ND. miR-221 is required for endothelial tip cell behaviors during vascular development. Dev Cell 2012; 22(2): 418-29.
79. [79] Liu X, Cheng Y, Zhang S, Lin Y, Yang J, Zhang C. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009; 104(4): 476-87.
80. [80] Liu X, Cheng Y, Yang J, Xu L, Zhang C. Cell-specific effects of miR-221/222 in vessels: Molecular mechanism and therapeutic application. J Mol Cell Cardiol. 2012; 52(1): 245-55.
81. [81] Torella D, Iaconetti C, Catalucci D, et al. MicroRNA-133 Controls Vascular Smooth Muscle Cell Phenotypic Switch In vitro and Vascular Remodeling In vivo. Circ Rese 2011; 109(8): 880-93.
82. [82] Sweetman D, Goljanek K, Rathjen T, et al. Specific requirements of MRFs for the expression of muscle specific microRNAs, miR-1, miR-206 and miR-133. Dev Biol 2008; 321(2): 491-9.
83. [83] Taganov KD, Boldin MP, Chang K-J, Baltimore D. NF-Bdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103(33): 12481-6.
84. [84] Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, Lindsay MA. Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol 2008; 180(8): 5689-98.
85. [85] Sun SG, Zheng B, Han M, et al. miR-146a and Kruppel-like factor 4 form a feedback loop to participate in vascular smooth muscle cell proliferation. EMBO Rep 2011; 12(1): 56-62.
86. [86] Li Q-J, Chau J, Ebert PJR, et al. miR-181a Is an Intrinsic Modulator of T Cell Sensitivity and Selection. Cell 2007; 129(1): 147-61.
87. [87] Chen C-Z, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303(5654): 83-6.
88. [88] Kazenwadel J, Michael MZ, Harvey NL. Prox1 expression is negatively regulated by miR-181 in endothelial cells. Blood 2010; 116(13): 2395-401.
89. [89] Chakraborty S, Mehtab S, Patwardhan A, Krishnan Y. Pri-miR-17-92a transcript folds into a tertiary structure and autoregulates its processing. RNA 2012; 18(5): 1014-28.
90. [90] Treguer K, Heinrich EM, Ohtani K, Bonauer A, Dimmeler S. Role of the microRNA-17-92 cluster in the endothelial differentiation of stem cells. J Vasc Res 2012; 49(5): 447-60.
91. [91] Philippe L, Alsaleh G, Suffert G, et al. TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes. J Immunol 2012; 188(1): 454-61.
92. [92] Liang Z, Li Y, Huang K, Wagar N, Shim H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011; 28(12): 3091-100.
93. [93] Iaconetti C, Polimeni A, Sorrentino S, et al. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res Cardiol 2012; 107(5): 296.
94. [94] Fang Y, Davies PF. Site-specific MicroRNA-92a regulation of krüppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol 2012; 32(4): 979-87.
95. [95] Boon RA, Hergenreider E, Dimmeler S. Atheroprotective mechanisms of shear stress-regulated microRNAs. Thromb Haemost 2012; 108(4): 616-20.
96. [96] Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 2011; 31(11): 2383-90.